Pharma’s Digital Directive: Not If, But How
Data science and data analytics offer operational advantages throughout large organizations. And the pharma should approach digital technology pragmatically, first applying the tools to what it already does.
You may also be interested in...
Joining the Novartis executive committee at the start of this week, newly appointed chief digital officer Bertrand Bodson reveals to Scrip how he sees digital health underpinninig the Swiss major’s future. Efforts at the company have already delivered a 10-15% reduction in patient enrolment times in pilot trials.
Duo aims to get Pear's THRIVE digital therapeutic approved, and to develop a new application to treat MS patients, then seek validation in clinical studies.
Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.